株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界のキナーゼ阻害剤市場:米国市場

Kinase Inhibitors: Global Markets -- Focus on the U.S.

発行 BCC Research 商品コード 246349
出版日 ページ情報 英文 122 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
世界のキナーゼ阻害剤市場:米国市場 Kinase Inhibitors: Global Markets -- Focus on the U.S.
出版日: 2012年06月30日 ページ情報: 英文 122 Pages
概要

世界のキナーゼ阻害剤市場は、2010年に281億米ドルに達し、2011年には291億米ドル近い市場規模を記録しました。今後は6.7%の年平均成長率(CAGR)で推移し、2016年には402億米ドルの市場規模に達すると予測されています。米国のキナーゼ阻害剤市場は、2010年に108億米ドル、2011年には104億米ドルとなりました。今後は、CAGR2.2%で拡大し、2016年には116億米ドルとなる見通しです。米国の抗体キナーゼ阻害剤市場は、2010年に76億米ドル、2011年には66億米ドルとなりました。今後は、CAGR-4%で縮小し、2016年には54億米ドルとなる見通しです。

当レポートでは、世界のキナーゼ阻害剤市場、特に米国市場の現状と見通しについて調査分析し、主要製品とその製造・供給事業者、新たな製品の開発動向、製品区分・用途別の市場規模実績・予測(〜2016年)、製品区分別の市場シェア、特許の状況、将来の方向性、主要企業のプロファイルなどをまとめ、概略以下の構成でお届けします。

第1章 イントロダクション

第2章 サマリー

第3章 概要

  • 定義
  • 酵素阻害薬
  • キナーゼ阻害薬

第4章 法規制的側面

  • 市場のリーダーとその製品

第5章 新たな開発動向

  • (レセプター)チロシンキナーゼ阻害薬(TKI)
  • (非レセプター)チロシンキナーゼ阻害薬(TKI)
  • マルチキナーゼ阻害薬
  • セリン・スレオニンキナーゼ阻害薬
  • その他

第6章 世界市場

  • 市場分析
    • チロシンキナーゼ阻害薬
    • セリン・スレオニンキナーゼ阻害薬
    • モノクローナル抗体キナーゼ阻害薬
  • 市場シェア
    • レセプターチロシンキナーゼ阻害薬
    • 非レセプターチロシンキナーゼ阻害薬
    • マルチターゲットキナーゼ阻害薬
    • セリン・スレオニンキナーゼ阻害薬
    • モノクローナル抗体キナーゼ阻害薬
  • 市場アプリケーション
    • 市場収益
    • 抗腫瘍薬
    • 免疫抑制剤
    • 加齢黄斑変性(AMD)
    • 市場シェア

第7章 米国市場

  • 市場分析
    • チロシンキナーゼ阻害薬
    • セリン・スレオニンキナーゼ阻害薬
    • モノクローナル抗体キナーゼ阻害薬
  • 主要企業の市場シェア
    • レセプターチロシンキナーゼ阻害薬
    • 非レセプターチロシンキナーゼ阻害薬
    • マルチターゲットキナーゼ阻害薬
    • セリン・スレオニンキナーゼ阻害薬
    • 抗体キナーゼ阻害薬
  • 市場アプリケーション
    • 市場収益
    • 抗腫瘍薬
    • 免疫抑制剤
    • 加齢黄斑変性(AMD)
    • 市場シェア

第8章 特許分析

第9章 現状

  • 癌とキナーゼ阻害薬
  • 複数の単一キナーゼ阻害薬 vs ひとつのマルチキナーゼ阻害薬
    • 効果
    • 耐性
    • 薬物動態
    • 腫瘍微小環境
    • 毒性
  • 将来の方向性

第10章 企業プロファイル

  • ABBOTT LABORATORIES
  • AMGEN INC.
  • ARQULE, INC.
  • ARRAY BIOPHARMA
  • ASTRAZENECA
  • AVEO PHARMACEUTICALS, INC.
  • BAYER AG
  • BRISTOL-MYERS SQUIBB
  • BOEHRINGER INGELHEIM
  • CYTRX CORPORATION
  • エーザイ
  • ETON BIOSCIENCE, INC.
  • EXELIXIS, INC.
  • GLAXOSMITHKLINE
  • MERCK SERONO SA
  • NOVARTIS INTERNATIONAL AG
  • OSI PHARMACEUTICALS LLC
  • PFIZER
  • ROCHE GROUP
  • S*BIO PTE LTD
  • SANOFI-AVENTIS
  • 武田薬品工業

第11章 用語

図表

目次
Product Code: BIO108A

The global kinase inhibitors market reached $28.1 billion in 2010 and nearly $29.1 billion in 2011. The market is expected to reach $40.2 billion by 2016, a compound annual growth rate (CAGR) of 6.7%.

The U.S. market for kinase inhibitors reached $10.8 billion in 2010 and came down to $10.4 billion in 2011. The market is expected to reach $11.6 billion by 2016, a CAGR of 2.2%.

The U.S. market for monoclonal antibody kinase inhibitors was $7.6 billion in 2010 and came down to $6.6 billion in 2011. This segment is expected to decrease at a CAGR of -4% and total $5.4 billion in 2016.

SUMMARY FIGURE
GLOBAL REVENUE OF KINASE INHIBITORS MARKET, 2009-2016
($ MILLIONS)

Source: BCC Research

STUDY OBJECTIVES

BCC's goal in conducting this study is to provide an overview of the current and future characteristics of the global market for kinase inhibitors. The key objective is to present a comprehensive analysis and the future direction of kinase inhibitors to provide an important tool for the usage of these types of enzyme inhibitors.

This report explores present and future strategies within the kinase inhibitors market, which includes tyrosine inhibitors, multi-target kinase inhibitors, serine/ threonine inhibitors and monoclonal antibody kinase inhibitors. The direction of the market, its setbacks and the needs of the market are discussed in this report. The classifications, comparisons and usage of these types of enzyme inhibitors are also examined in the report.

A detailed analysis of the kinase inhibitors industry structure has been conducted. Revenues are broken down by region. Sales figures are estimated for the five-year period from 2011 through 2016.

Applications for kinase inhibitors are also discussed separately in the report, with emphasis on the usage of the inhibitors in therapeutic categories and various disease sectors. The report also covers significant patents and a summary of patents awarded in each category.

REASONS FOR DOING THIS STUDY

Extensive research in the field of kinase inhibitors has revealed their target-specific functionality in being able to provide therapeutic treatments for various chronic diseases. Modern industries have now begun to explore the advantages of kinase inhibitors in their productions and processes. This has led to the steady market for them.

R&D spending along with increasing competition, patent expiries and new technologies are directing kinase inhibitors to new directions. The new advancements, new product launches and the changing lifestyle have influenced the market to grow in the foreseeable future. This study looks at almost all the systems affected by these factors.

Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strengths and weaknesses of each type/ technology in light of the new technologies, growing competition and changing customer needs.

SCOPE OF THE STUDY

The scope of this study encompasses kinase inhibitors in pharmaceutical and biotechnology markets. BCC analyzes each market and its applications, regulatory environment, technology, market projections and market share. Technological issues include the latest trends and developments. The emerging market for enzyme inhibitors includes India, China, Japan, South Korea, Taiwan, Canada, Africa, Australia and New Zealand and others countries.

INFORMATION SOURCES

Many companies active in the kinase inhibitor industry were surveyed to obtain data for this study. Included were manufacturers and end users of kinase inhibitors in therapeutic categories and various disease sectors industries. Data were gathered from various industry sources. BCC spoke with officials within the industry, consulted newsletters, company literature, product literature, and a host of technical articles, journals, indexes, and abstracts. Exhaustive investigations of databases by key terminology were conducted. In addition, data were compiled from current financial, trade and government sources.

ABOUT THE AUTHOR

A team of professionals in the biotechnology industry carried out this study. The project manager is Shalini S. Dewan, who holds a master's degree in pharmaceutical chemistry and has over 14 years of industry experience. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Shalini was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S.

Table of Contents

Kinase Inhibitors: Global Markets -- Focus on the U.S.

Chapter - 1: INTRODUCTION - Complimentary

  • STUDY OBJECTIVES
  • REASONS FOR DOING THIS STUDY
  • INTENDED AUDIENCE
  • SCOPE OF THE STUDY
  • METHODOLOGY
  • INFORMATION SOURCES
  • ABOUT THE AUTHOR
  • RELATED BCC RESEARCH REPORTS
  • BCC ONLINE SERVICES
  • DISCLAIMER

Chapter - 2: SUMMARY

  • Table Summary: GLOBAL REVENUE OF KINASE INHIBITORS MARKET, THROUGH 2016
  • Figure Summary: GLOBAL REVENUE OF KINASE INHIBITORS MARKET, 2009-2016

Chapter - 3: OVERVIEW

  • DEFINITIONS
  • ENZYME INHIBITORS
  • KINASE INHIBITORS
  • CLASSIFICATION BY TYPES OF AMINO ACID PHOSPHORYLATION
  • CLASSIFICATION BY SITE OF ACTION

Chapter - 4: REGULATORY ASPECTS

  • MARKET LEADERS AND THEIR PRODUCTS FOR KINASE INHIBITORS
    • Table 13: LEADING MANUFACTURERS AND SUPPLIERS OF RECEPTOR TYROSINE KINASE INHIBITORS
    • Table 14: LEADING MANUFACTURERS AND SUPPLIERS OF NON-RECEPTOR TYROSINE KINASE INHIBITORS
    • Table 15: LEADING MANUFACTURERS AND SUPPLIERS OF MULTI-TARGET TYROSINE KINASE INHIBITORS
    • Table 16: LEADING MANUFACTURERS AND SUPPLIERS OF SERINE AND THREONINE KINASE INHIBITORS
    • Table 17: LEADING MANUFACTURERS AND SUPPLIERS OF ANTIBODY KINASE INHIBITORS

Chapter - 5: NEW DEVELOPMENTS

  • (RECEPTOR) TYROSINE KINASE INHIBITORS (TKIS)
  • (NON-RECEPTOR) TYROSINE KINASE INHIBITORS (TKIS)
  • MULTIKINASE INHIBITORS
  • SERINE/THREONINE KINASE INHIBITOR
  • OTHER KINASE INHIBITOR PRODUCTS UNDER DEVELOPMENT
    • Table 18: CLINICAL TRIALS IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TKIS
    • Table 19: CLINICAL TRIALS IN HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) TKIS
    • Table 20: CLINICAL TRIALS IN PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) TKIS
    • Table 21: CLINICAL TRIALS IN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR (VEGFR) TKIS

Chapter - 6: GLOBAL MARKETS

  • MARKET ANALYSIS
  • MARKET SHARE
  • MARKET BY APPLICATIONS
    • Table 29: GLOBAL MARKET FOR KINASE INHIBITORS, THROUGH 2016
    • Figure 1: GLOBAL MARKET FOR KINASE INHIBITORS, 2009-2016

Chapter - 7: MARKETS IN THE UNITED STATES

  • MARKET ANALYSIS
  • MARKET SHARE OF INDUSTRY LEADERS IN U.S
  • MARKET APPLICATIONS
    • Table 45: U.S. MARKET FOR KINASE INHIBITORS, THROUGH 2016
    • Figure 17: U.S. MARKET FOR KINASE INHIBITORS, 2009-2016

Chapter - 8: PATENT ANALYSIS

  • PATENTS BY YEAR
  • PATENTS BY CATEGORY
  • PATENTS BY TYPE
  • PATENTS BY COMPANY
  • PATENTS BY COUNTRY
  • PATENTS BY ASSIGNEE
    • Table 61: NUMBER OF SIGNIFICANT PATENTS BY YEAR, 2008 TO END OF FEBRUARY 2012
    • Figure 33: NUMBER OF PATENTS BY YEAR, 2008 TO END OF FEBRUARY 2012
    • Figure 34: NUMBER OF PATENTS BY YEAR, 2008 TO END OF FEBRUARY 2012

Chapter - 9: CURRENT STATUS

  • CANCER AND KINASE INHIBITORS
  • MULTIPLE SINGLE KINASE INHIBITORS VERSUS SINGLE MULTIKINASE INHIBITORS
  • FUTURE DIRECTIONS

Chapter - 10: COMPANY PROFILES

  • ABBOTT LABORATORIES
  • AMGEN INC.
  • ARQULE, INC.
  • ARRAY BIOPHARMA
  • ASTRAZENECA
  • AVEO PHARMACEUTICALS, INC.
  • BAYER AG
  • BRISTOL-MYERS SQUIBB
  • BOEHRINGER INGELHEIM
  • CYTRX CORPORATION
  • EISAI INC
  • ETON BIOSCIENCE, INC.
  • EXELIXIS, INC.
  • GLAXOSMITHKLINE
  • MERCK SERONO SA
  • NOVARTIS INTERNATIONAL AG
  • OSI PHARMACEUTICALS LLC
  • PFIZER
  • ROCHE GROUP
  • S*BIO PTE LTD
  • SANOFI-AVENTIS
  • TAKEDA PHARMACEUTICALS

Chapter - 11: APPENDIX: ABBREVIATIONS

List of Tables

  • Summary Table: GLOBAL REVENUE OF KINASE INHIBITORS MARKET, THROUGH 2016
  • Table 1: CLASSIFICATION OF ENZYME INHIBITORS
  • Table 2: HISTORY OF PROTEIN KINASES
  • Table 3: TYPES OF KINASE INHIBITORS
  • Table 4: ATP COMPETITIVE AND NON-COMPETITIVE INHIBITORS
  • Table 5: TYPES OF SERINE/THREONINE KINASE INHIBITORS
  • Table 6: TYPES OF RECEPTOR TYROSINE KINASE INHIBITORS
  • Table 7: TYPES OF NON-RECEPTOR TYROSINE KINASE INHIBITORS
  • Table 8: CLASSIFICATION OF KINASE INHIBITORS BY SITE OF ACTION
  • Table 9: FDA-APPROVED KINASE INHIBITORS, 2008 TO FEBRUARY 2012
  • Table 10: EMA-APPROVED KINASE INHIBITORS 2008 TO FEBRUARY 2012
  • Table 11: SAFETY ALERTS AND WARNINGS FOR KINASE INHIBITORS 2008 TO FEBRUARY 2012
  • Table 12: NEW DRUG APPLICATIONS OF KINASE INHIBITORS
  • Table 13: LEADING MANUFACTURERS AND SUPPLIERS OF RECEPTOR TYROSINE KINASE INHIBITORS
  • Table 14: LEADING MANUFACTURERS AND SUPPLIERS OF NON-RECEPTOR TYROSINE KINASE INHIBITORS
  • Table 15: LEADING MANUFACTURERS AND SUPPLIERS OF MULTI-TARGET TYROSINE KINASE INHIBITORS
  • Table 16: LEADING MANUFACTURERS AND SUPPLIERS OF SERINE AND THREONINE KINASE INHIBITORS
  • Table 17: LEADING MANUFACTURERS AND SUPPLIERS OF ANTIBODY KINASE INHIBITORS
  • Table 18: CLINICAL TRIALS IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TKIS
  • Table 19: CLINICAL TRIALS IN HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) TKIS
  • Table 20: CLINICAL TRIALS IN PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) TKIS
  • Table 21: CLINICAL TRIALS IN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR (VEGFR) TKIS
  • Table 22: CLINICAL TRIALS IN BCR-ABL TYROSINE KINASE INHIBITORS
  • Table 23: CLINICAL TRIALS IN JANUS KINASE (JAK) INHIBITORS
  • Table 24: CLINICAL TRIALS IN SPLEEN TYROSINE KINASE (SYK) INHIBITORS
  • Table 25: CLINICAL TRIALS IN MULTIKINASE INHIBITORS
  • Table 26: CLINICAL TRIALS IN B-RAF KINASE INHIBITORS
  • Table 27: CLINICAL TRIALS IN MAP/MEK INHIBITORS
  • Table 28: CLINICAL TRIALS IN PI3K INHIBITORS
  • Table 29: GLOBAL MARKET FOR KINASE INHIBITORS, THROUGH 2016
  • Table 30: GLOBAL MARKET FOR TYROSINE KINASE INHIBITORS THROUGH 2016
  • Table 31: GLOBAL MARKET FOR RECEPTOR TYROSINE KINASE INHIBITOR THROUGH 2016
  • Table 32: GLOBAL MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITOR THROUGH 2016
  • Table 33: GLOBAL MARKET FOR MULTIKINASE TYROSINE INHIBITOR THROUGH 2016
  • Table 34: GLOBAL MARKET FOR SERINE/THREONINE KINASE INHIBITOR THROUGH 2016
  • Table 35: GLOBAL MARKET FOR MONOCLONAL ANTIBODY KINASE INHIBITOR, THROUGH 2016
  • Table 36: RECEPTOR TYROSINE KINASE INHIBITOR MARKET SHARE BY REGION, 2010
  • Table 37: MULTI-TARGET KINASE INHIBITOR MARKET SHARE BY REGION, 2010
  • Table 38: SERINE/THREONINE KINASE INHIBITOR MARKET SHARE BY REGION, 2010
  • Table 39: MONOCLONAL ANTIBODY KINASE INHIBITOR MARKET SHARES BY REGION, 2010
  • Table 40: GLOBAL MARKET FOR KINASE INHIBITORS BY APPLICATIONS, THROUGH 2016
  • Table 41: GLOBAL MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC AGENTS, THROUGH 2016
  • Table 42: GLOBAL MARKET FOR KINASE INHIBITORS USED AS IMMUNOSUPPRESSANTS, THROUGH 2016
  • Table 43: GLOBAL MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR DEGENERATION, THROUGH 2016
  • Table 44: GLOBAL MARKET SHARE OF APPLICATIONS OF KINASE INHIBITORS, 2010
  • Table 45: U.S. MARKET FOR KINASE INHIBITORS, THROUGH 2016
  • Table 46: U.S. MARKET FOR TYROSINE KINASE INHIBITORS, THROUGH 2016
  • Table 47: U.S. MARKET FOR RECEPTOR TYROSINE KINASE INHIBITOR, THROUGH 2016
  • Table 48: U.S. MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITOR, THROUGH 2016
  • Table 49: U.S. MARKET FOR MULTIKINASE TYROSINE INHIBITOR, THROUGH 2016
  • Table 50: U.S. MARKET FOR SERINE/THREONINE KINASE INHIBITOR, THROUGH 2016
  • Table 51: U.S. MARKET FOR MONOCLONAL ANTIBODY KINASE INHIBITOR, THROUGH 2016
  • Table 52: U.S. MARKET SHARES OF RECEPTOR TYROSINE KINASE INHIBITOR MANUFACTURERS, 2010
  • Table 53: U.S. MARKET SHARES OF MULTI-TARGET KINASE INHIBITOR MANUFACTURERS, 2010
  • Table 54: U.S. MARKET SHARES OF SERINE/ THREONINE KINASE INHIBITOR MANUFACTURERS, 2010
  • Table 55: U.S. MARKET SHARE OF ANTIBODY KINASE INHIBITOR MANUFACTURERS, 2010
  • Table 56: U.S. MARKET FOR KINASE INHIBITORS BY APPLICATION, THROUGH 2016
  • Table 57: U.S. MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC AGENTS, THROUGH 2016
  • Table 58: U.S. MARKET FOR KINASE INHIBITORS USED AS IMMUNOSUPPRESSANTS,THROUGH 2016
  • Table 59: U.S. MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR DEGENERATION, THROUGH 2016
  • Table 60: MARKET SHARE OF APPLICATIONS OF KINASE INHIBITORS IN U.S., 2010
  • Table 61: NUMBER OF SIGNIFICANT PATENTS BY YEAR, 2008 TO END OF FEBRUARY 2012
  • Table 62: PATENTS BY CATEGORY FOR KINASE INHIBITORS 2008 TO END OF FEBRUARY 2012
  • Table 63: PATENTS BY TYPE FOR TYROSINE KINASE INHIBITORS 2008 TO END OF FEBRUARY 2012
  • Table 64: PATENTS BY TYPE FOR SERINE/THREONINE KINASE INHIBITORS, 2008 TO END OF FEBRUARY 2012
  • Table 65: NUMBER OF U.S. PATENTS BY COMPANY FOR INDUSTRIAL ENZYMES, 2008 TO END OF FEBRUARY 2012
  • Table 66: NUMBER OF U.S. PATENTS BY COUNTRY FOR KINASE INHIBITORS, 2008 TO END OF FEBRUARY 2012
  • Table 67: PATENT SHARE BY COUNTRY FOR KINASE INHIBITORS, 2010 - 2012
  • Table 68: PATENTS BY ASSIGNEE FOR KINASE INHIBITORS, 2008 THROUGH END OF FEBRUARY 2012

List of Figures

  • Summary Figure: GLOBAL REVENUE OF KINASE INHIBITORS MARKET, 2009-2016
  • Figure 1: GLOBAL MARKET FOR KINASE INHIBITORS, 2009-2016
  • Figure 2: GLOBAL MARKET FOR TYROSINE KINASE INHIBITORS 2009-2016
  • Figure 3: GLOBAL MARKET FOR RECEPTOR TYROSINE KINASE INHIBITOR, 2009-2016
  • Figure 4: GLOBAL MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITOR, 2009-2016
  • Figure 5: GLOBAL MARKET FOR MULTIKINASE TYROSINE INHIBITOR, 2009-2016
  • Figure 6: GLOBAL MARKET FOR SERINE/THREONINE KINASE INHIBITORS, 2009-2016
  • Figure 7: GLOBAL MARKET FOR MONOCLONAL ANTIBODY KINASE INHIBITOR, 2009-2016
  • Figure 8: RECEPTOR TYROSINE KINASE INHIBITOR MARKET SHARE BY REGION, 2010
  • Figure 9: MULTI-TARGET KINASE INHIBITOR MARKET SHARE BY REGION, 2010
  • Figure 10: SERINE/THREONINE KINASE INHIBITOR MARKET SHARE BY REGION, 2010
  • Figure 11: MONOCLONAL ANTIBODY KINASE INHIBITOR MARKET SHARES BY REGION, 2010
  • Figure 12: GLOBAL MARKET FOR KINASE INHIBITORS BY APPLICATIONS, 2009-2016
  • Figure 13: GLOBAL MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC AGENTS, 2009-2016
  • Figure 14: GLOBAL MARKET FOR KINASE INHIBITORS USED AS IMMUNOSUPPRESSANTS, 2009-2016
  • Figure 15: GLOBAL MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR DEGENERATION, 2009-2016
  • Figure 16: GLOBAL MARKET SHARE OF APPLICATIONS OF KINASE INHIBITORS, 2010
  • Figure 17: U.S. MARKET FOR KINASE INHIBITORS, 2009-2016
  • Figure 18: U.S. MARKET FOR TYROSINE KINASE INHIBITORS, 2009-2016
  • Figure 19: U.S. MARKET FOR RECEPTOR TYROSINE KINASE INHIBITOR, 2009-2016
  • Figure 20: U.S. MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITOR, 2009-2016
  • Figure 21: U.S. MARKET FOR MULTIKINASE TYROSINE INHIBITOR, 2009-2016
  • Figure 22: U.S. MARKET FOR SERINE/THREONINE KINASE INHIBITOR, 2009-2016
  • Figure 23: U.S. MARKET FOR MONOCLONAL ANTIBODY KINASE INHIBITOR 2009-2016
  • Figure 24: U.S. MARKET SHARES OF RECEPTOR TYROSINE KINASE INHIBITOR MANUFACTURERS, 2010
  • Figure 25: U.S. MARKET SHARES OF MULTI-TARGET KINASE INHIBITOR MANUFACTURERS, 2010
  • Figure 26: U.S. MARKET SHARES OF SERINE/ THREONINE KINASE INHIBITOR MANUFACTURERS, 2010
  • Figure 27: U.S. MARKET SHARE OF ANTIBODY KINASE INHIBITOR MANUFACTURERS, 2010
  • Figure 28: U.S. MARKET FOR KINASE INHIBITORS BY APPLICATION, 2009-2016
  • Figure 29: U.S. MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC AGENTS, 2009-2016
  • Figure 30: U.S. MARKET FOR KINASE INHIBITORS USED AS IMMUNOSUPPRESSANTS, 2009-2016
  • Figure 31: U.S. MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR DEGENERATION, 2009-2016
  • Figure 32: MARKET SHARE OF APPLICATIONS OF KINASE INHIBITORS IN U.S., 2010
  • Figure 33: NUMBER OF PATENTS BY YEAR, 2008 TO END OF FEBRUARY 2012
  • Figure 34: NUMBER OF PATENTS BY YEAR, 2008 TO END OF FEBRUARY 2012
  • Figure 35: PATENTS BY CATEGORY FOR KINASE INHIBITORS 2008 TO END OF FEBRUARY 2012
  • Figure 36: PATENTS BY TYPE FOR TYROSINE KINASE INHIBITORS 2008 TO END OF FEBRUARY 2012
  • Figure 37: PATENTS BY TYPE FOR SERINE/THREONINE KINASE INHIBITORS, 2008 TO END OF FEBRUARY 2012
  • Figure 38: NUMBER OF U.S. PATENTS BY COUNTRY FOR KINASE INHIBITORS, 2008 TO END OF FEBRUARY 2012
  • Figure 39: PATENT SHARES BY COUNTRY FOR KINASE INHIBITORS, 2010 - 2012
  • Figure 40: PATENTS BY ASSIGNEE FOR KINASE INHIBITORS, 2008 THROUGH END OF FEBRUARY 2012
Back to Top